StockNews.AISignal intelligence
aTyr Pharma, Inc. · NASDAQ · Healthcare
Browse public ATYR signals with their source context and measured market impact. Open any signal for its permanent analysis page.
ATYR announced FDA alignment on a Phase 3 protocol for efzofitimod in pulmonary sarcoidosis with restrictive lung disease, centering on FVC change at week 48. The 54-week global trial plans two cohorts (up to 372 patients) with IV dosing every 3 weeks and US/Europe regulatory submissions planned for late 2026. Ongoing financing needs and execution risk will influence timing and potential upside.
View signal analysisaTyr Pharma's stock fell over 81% following failed Phase 3 trial results. Trial for efzofitimod missed its primary endpoint, prompting investor sell-off. FDA engagement planned to explore regulatory options for efzofitimod. Some secondary endpoints showed promising results, despite primary miss. Stock currently priced at $1.06 with high session volume.
View signal analysisaTyr Pharma's drug missed primary endpoint in late-stage pulmonary sarcoidosis trial. Failure may impact investor confidence and future funding.
View signal analysis